Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy
about
Desmuslin, an intermediate filament protein that interacts with alpha -dystrobrevin and desminDystrophins and dystrobrevins.Destabilization of the dystrophin-glycoprotein complex without functional deficits in alpha-dystrobrevin null muscleProteomic analysis reveals new cardiac-specific dystrophin-associated proteinsMyocilin interacts with syntrophins and is member of dystrophin-associated protein complexPhosphorylation on threonine 11 of β-dystrobrevin alters its interaction with kinesin heavy chainThe Dystrophin Complex: Structure, Function, and Implications for TherapyCharacterization of human alpha-dystrobrevin isoforms in HL-60 human promyelocytic leukemia cells undergoing granulocytic differentiation.Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx miceConservation of components of the dystrophin complex in Drosophila.Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications.The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era.Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stressDystrophin-glycoprotein complex: post-translational processing and dystroglycan function.Sarcoglycanopathies: molecular pathogenesis and therapeutic prospectsViral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advancesAssembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domainAlpha1-syntrophin-deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration.Tyrosine-phosphorylated and nonphosphorylated isoforms of alpha-dystrobrevin: roles in skeletal muscle and its neuromuscular and myotendinous junctions.Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.Ring chromosome 18 in combination with 18q12.1 (DTNA) interstitial microdeletion in a patient with multiple congenital defects.Processing and assembly of the dystrophin glycoprotein complex.Inhibition of proteasome activity promotes the correct localization of disease-causing alpha-sarcoglycan mutants in HEK-293 cells constitutively expressing beta-, gamma-, and delta-sarcoglycan.Dilated cardiomyopathy mutations in δ-sarcoglycan exert a dominant-negative effect on cardiac myocyte mechanical stability.Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy.Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophyDystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx miceCurrent Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy.S151A δ-sarcoglycan mutation causes a mild phenotype of cardiomyopathy in mice.The role of α-dystrobrevin in striated muscle.Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.Finding the sweet spot: assembly and glycosylation of the dystrophin-associated glycoprotein complex.Costamere proteins and their involvement in myopathic processes.Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stressesCell entry of lymphocytic choriomeningitis virus is restricted in myotubes.α-Dystrobrevin distribution and association with other proteins in human promyelocytic NB4 cells treated for granulocytic differentiation.Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy
P2860
Q24291234-23A18225-DA63-45B0-BF31-6382F2DF01FBQ24805434-4F9C40BE-F70F-46A7-B935-97C6D7003CB2Q28473016-F90AC525-F391-4C73-937E-16C18F0C1248Q28482614-CA7F85FA-1538-4122-AC94-21AA65A89A0AQ28586144-2BF5487B-AF4B-4366-9B1B-3C6151EDF127Q28587447-3F8C6D6F-6060-433D-9C7A-625763C3B385Q30376293-C8A8BD82-5FAF-4368-ABBC-77D0C79D3D87Q30873797-65747938-D46E-4A9F-AC48-EF6E45A9D2CBQ33290644-F39FBBD5-CDBF-49AC-BCE9-873A2193F797Q34052934-9CD5C340-1BB4-466F-8C41-EBF25620B3AEQ34233835-6C73468F-4378-46BC-903B-8B4846105BD6Q34483183-1E74251F-6813-444D-816B-340D2DEEEB14Q34567946-051589C8-537A-4254-8D40-B5194E3161A6Q34575694-844321E3-89F5-478D-9451-82B6206FFAB9Q34737660-50F9A418-9C16-4E9B-AE1A-548126DDD3ABQ35056189-72025765-B5DC-4984-96C7-1CE6D4801004Q35758335-07464058-F4AF-45A4-AC90-ED23D4875DB2Q35847178-25E871A7-C3E6-4463-BF49-DB01FFF1B788Q36293809-5FC36E07-0FCE-41B1-91F9-1A940AD258AEQ36324019-E1850F67-601A-4604-AD33-64101AAD7DA4Q36324225-AFB9E1F5-FFED-4453-BA1C-4F5CBA74C9EBQ36422465-0E3940D4-3139-4D5E-9D28-FAF9C04753B7Q36592081-EFDE24E6-DAB1-48FA-A549-D47BC7E37A29Q36726710-211ECA0A-3C4E-41B1-806C-C796B120988FQ36734894-5A2BEE8D-136E-40C6-B04D-C348CF86329DQ36902560-0531838B-EE8B-4F04-8D00-0B962CFBE674Q37053612-40388CC0-1292-46F6-8D24-E16E8A1A2BAAQ37105210-6CBC6269-596E-4C92-876D-8E10019F7F67Q37111368-644A0A8F-B687-4E46-8148-0ADB28651CA0Q37128346-1E71D023-BD88-4002-B74C-850604571D7CQ37277411-70C3E74C-0BE7-4002-B7F7-4D63314E00E7Q37397675-D13B97F2-738F-43B7-9392-D163C3F7CD45Q37889650-416CACD6-9638-45AC-939F-8B5CE8E80883Q38056065-7B3DF862-9CFD-4D63-95DB-A0953A97F1F1Q38240078-6DA9EC6D-FE13-4278-B334-56E464AB8331Q38531654-597BD1FB-7DEF-495E-80EB-E1D0E95890AEQ38623198-F2A844AA-6208-4EE8-856F-5C872B730CEAQ38985001-7E2AF60B-E0C4-425E-987F-1E73F0F6B751Q39746483-DA7F93CD-80B4-4CCA-9A85-19B66BD6E0D9Q40613995-C48FA6DD-B9D4-48C8-8C3F-D4C36535BC4F
P2860
Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@ast
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@en
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@en-gb
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@nl
type
label
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@ast
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@en
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@en-gb
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@nl
prefLabel
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@ast
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@en
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@en-gb
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@nl
P2093
P921
P3181
P356
P1476
Biochemical evidence for assoc ...... nderstanding sarcoglycanopathy
@en
P2093
E Wakabayashi-Takai
M Ishikawa-Sakurai
P304
P3181
P356
10.1093/HMG/9.7.1033
P407
P577
2000-04-12T00:00:00Z